Shares of Boston Scientific (NYSE: BSX) came under pressure after an analyst reduced his price target on the medical-device maker, citing a weaker-than-expected outlook for 2026 despite a solid fourth-quarter performance.

Analyst Mike Matson of Needham & Company maintained a Buy rating on the stock but lowered his price target to $97 from $121, pointing to decelerating growth trends and guidance that fell modestly below Wall Street expectations. Boston Scientific reported fourth-quarter revenue of $5.29 billion and adjusted earnings of $0.80 per share, both slightly ahead of consensus estimates. However, organic revenue growth slowed during the quarter, reflecting increased competition in certain cardiovascular therapies and softer momentum across parts of the company’s MedSurg portfolio.

In commentary accompanying the earnings release, management projected 2026 organic revenue growth of approximately 10% to 11%, a step down from the pace recorded in 2025. The company also forecast adjusted earnings per share of $3.43 to $3.49 for the year, with the midpoint narrowly below analyst expectations.

The more cautious outlook overshadowed the quarterly beat, with investors focusing on signs of moderating demand in some product categories and the challenges of sustaining recent growth rates. Boston Scientific is also preparing to integrate its recently announced $14.5 billion acquisition of Penumbra, which adds near-term complexity to its financial outlook. 

For the first quarter of 2026, the company expects adjusted earnings of $0.78 to $0.80 per share, roughly in line with consensus forecasts. 

About Boston Scientific

Boston Scientific (NYSE: BSX) is a global medical technology company that develops and manufactures devices used in interventional medical specialties, including cardiology, rhythm management, endoscopy, urology, and neuromodulation. The company serves healthcare providers worldwide with a focus on minimally invasive solutions.

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.